Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atopic Dermatitis (Pediatric) (US)
Atopic dermatitis (AD) is a chronic, itchy, inflammatory skin disease often starting in childhood. It is usually treated with topical immunotherapy. Refractory cases may need systemic immunomodulators with long-term risks. The launch of biologics (Dupixent, Adbry, Ebglyss, Nemluvio), JAK inhibitors (Rinvoq, Cibinqo, Opzelura), and non-steroidal agents (Vtama, Zoryve, Eucrisa) has greatly expanded treatment options for pediatric AD patients across the severity spectrum. This claims data analysis explores the usage pattern of newer therapies relative to historical mainstays, offering insight into evolving drug trends in pediatric AD.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric AD patients? What are the quarterly trends in prescribing recently treated and newly diagnosed pediatric AD patients?
- How have newer-to-market targeted therapies been integrated into the treatment algorithm, and what is their source of business?
- What percentage of pediatric AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric AD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
Geography: United States
Real-world data: U.S. pharmacy and medical claims data
Key drugs covered: Adbry, Cibinqo, Dupixent, Ebglyss, Nemluvio, Opzelura, Rinvoq, Vtama, oral immunosuppressants, corticosteroids (topical and oral), topical calcineurin inhibitors
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
